Literature DB >> 10081936

Do beta-amyloid (Abeta) deposits in patients with Alzheimer's disease and Down's syndrome grow according to the log-normal model?

R A Armstrong1.   

Abstract

The size frequency distributions of diffuse, primitive and classic beta-amyloid (Abeta) deposits were studied in single sections of cortical tissue from patients with Alzheimer's disease (AD) and Down's syndrome (DS) and compared with those predicted by the log-normal model. In a sample of brain regions, these size distributions were compared with those obtained by serial reconstruction through the tissue and the data used to adjust the size distributions obtained in single sections. The adjusted size distributions of the diffuse, primitive and classic deposits deviated significantly from a log-normal model in AD and DS, the greatest deviations from the model being observed in AD. More Abeta deposits were observed close to the mean and fewer in the larger size classes than predicted by the model. Hence, the growth of Abeta deposits in AD and DS does not strictly follow the log-normal model, deposits growing to within a more restricted size range than predicted. However, Abeta deposits grow to a larger size in DS compared with AD which may reflect differences in the mechanism of Abeta formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081936     DOI: 10.1016/s0304-3940(99)00009-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

1.  Size frequency distribution of prion protein (PrP) aggregates in variant Creutzfeldt-Jakob disease (vCJD).

Authors:  R A Armstrong; N J Cairns; J W Ironside; P L Lantos
Journal:  J Neural Transm (Vienna)       Date:  2005-03-23       Impact factor: 3.575

2.  Size frequency distribution of the beta-amyloid (abeta) deposits in dementia with Lewy bodies with associated Alzheimer's disease pathology.

Authors:  Richard A Armstrong; Nigel J Cairns
Journal:  Neurol Sci       Date:  2009-09-19       Impact factor: 3.307

3.  Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice.

Authors:  Eric A Tanifum; Indrani Dasgupta; Mayank Srivastava; Rohan C Bhavane; Li Sun; John Berridge; Hoda Pourgarzham; Rashmi Kamath; Gabriela Espinosa; Stephen C Cook; Jason L Eriksen; Ananth Annapragada
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

4.  A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain.

Authors:  Floyd Sarsoza; Tommy Saing; Rakez Kayed; Robert Dahlin; Malcolm Dick; Camille Broadwater-Hollifield; Scott Mobley; Ira Lott; Eric Doran; Daniel Gillen; Clifford Anderson-Bergman; David H Cribbs; Charles Glabe; Elizabeth Head
Journal:  Acta Neuropathol       Date:  2009-04-10       Impact factor: 17.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.